

Optimizing Patient Outcomes in Bipolar Disorder: Long-term Management of Major Depressive Episodes - Tweeterial #6

References

Tweet 4

Boyce P, Irwin L, Morris G, et al. Long-acting injectable antipsychotics as maintenance treatments for bipolar disorder-A critical review of the evidence. *Bipolar Disord*. 2018;20 Suppl 2:25-36. doi:10.1111/bdi.12698

García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients. *J Clin Psychopharmacol*. 2016;36(4):355-371. doi:10.1097/JCP.0000000000000523

Tweet 5

Chakrabarti S. Treatment alliance and adherence in bipolar disorder. *World J Psychiatry*. 2018;8(5):114-124. doi:10.5498/wjp.v8.i5.114

Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord*. 2018;20(2):97-170. doi:10.1111/bdi.12609

Tweet 7

Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord*. 2018;20(2):97-170. doi:10.1111/bdi.12609

Tweet 8

Baldessarini RJ, Vázquez GH, Tondo L. Bipolar depression: a major unsolved challenge. *Int J Bipolar Disord*. 2020;8(1):1. Published 2020 Jan 6. doi:10.1186/s40345-019-0160-1

Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord*. 2018;20(2):97-170. doi:10.1111/bdi.12609

Tweet 10

García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients. *J Clin Psychopharmacol*. 2016;36(4):355-371. doi:10.1097/JCP.0000000000000523

Tweet 12

Citrome L. Food and Drug Administration-approved treatments for acute bipolar depression: what we have and what we need. *J Clin Psychopharmacol*. 2020;40(4):334-338. doi:10.1097/JCP.0000000000001227

Ostacher M, Ng-Mak D, Patel P, Ntais D, Schlueter M, Loebel A. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis. *World J Biol Psychiatry*. 2018;19(8):586-601. doi:10.1080/15622975.2017.1285050

Tweet 13

Abdel-Baki A, Lesage A, Nicole L, et al. Schizophrenia, an illness with bad outcome: myth or reality? *Can J Psychiatry*. 2011;56(2):92–101.

Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. *Arch Gen Psychiatry*. 2005;62(7):717–724.

García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients. *J Clin Psychopharmacol*. 2016;36(4):355-371. doi:10.1097/JCP.0000000000000523

Martinez-Aran A, Scott J, Colom F, et al. Treatment nonadherence and neurocognitive impairment in bipolar disorder. *J Clin Psychiatry*. 2009;70(7):1017–1023.

Perkins DO. Predictors of noncompliance in patients with schizophrenia. *J Clin Psychiatry*. 2002;63(12):1121–1128.

Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. *J Clin Psychiatry*. 2009;70(Suppl 4):1–46.

Glossary

CANMAT, Canadian Network for Mood and Anxiety Treatments

Collab, collaborative

Cont, continued

ER, extended release

IR, immediate release

ISBD, International Society for Bipolar Disorders

IR, immediate release

MDE, major depressive episode

Mos, months

OFC, olanzapine-fluoxetine combination

Pt, patient

QOL, quality of life

SDM, shared decision-making

T2DM, Type 2 diabetes mellitus

Tx, treatment

w/, with

XR, extended release